作者
Martin B Leon, Michael J Mack, Rebecca T Hahn, Vinod H Thourani, Raj Makkar, Susheel K Kodali, Maria C Alu, Mahesh V Madhavan, Katherine H Chau, Mark Russo, Samir R Kapadia, S Chris Malaisrie, David J Cohen, Philipp Blanke, Jonathon A Leipsic, Mathew R Williams, James M McCabe, David L Brown, Vasilis Babaliaros, Scott Goldman, Howard C Herrmann, Wilson Y Szeto, Philippe Genereux, Ashish Pershad, Michael Lu, John G Webb, Craig R Smith, Philippe Pibarot, PARTNER 3 Investigators
发表日期
2021/3/9
期刊
Journal of the American College of Cardiology
卷号
77
期号
9
页码范围
1149-1161
出版商
American College of Cardiology Foundation
简介
Background
In low surgical risk patients with symptomatic severe aortic stenosis, the PARTNER 3 (Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis) trial demonstrated superiority of transcatheter aortic valve replacement (TAVR) versus surgery for the primary endpoint of death, stroke, or re-hospitalization at 1 year.
Objectives
This study determined both clinical and echocardiographic outcomes between 1 and 2 years in the PARTNER 3 trial.
Methods
This study randomly assigned 1,000 patients (1:1) to transfemoral TAVR with the SAPIEN 3 valve versus surgery (mean Society of Thoracic Surgeons score: 1.9%; mean age: 73 years) with clinical and echocardiography follow-up at 30 days and at 1 and 2 years. This study assessed 2-year rates of the primary endpoint and several secondary endpoints (clinical, echocardiography, and quality-of-life …
学术搜索中的文章
MB Leon, MJ Mack, RT Hahn, VH Thourani, R Makkar… - Journal of the American College of Cardiology, 2021